Publication: Spiroindolones, a potent compound class for the treatment of malaria
Issued Date
2010-09-03
Resource Type
ISSN
10959203
00368075
00368075
Other identifier(s)
2-s2.0-77956280420
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Science. Vol.329, No.5996 (2010), 1175-1180
Suggested Citation
Matthias Rottmann, Case McNamara, Bryan K.S. Yeung, Marcus C.S. Lee, Bin Zou, Bruce Russell, Patrick Seitz, David M. Plouffe, Neekesh V. Dharia, Jocelyn Tan, Steven B. Cohen, Kathryn R. Spencer, Gonzalo E. González-Páez, Suresh B. Lakshminarayana, Anne Goh, Rossarin Suwanarusk, Timothy Jegla, Esther K. Schmitt, Hans Peter Beck, Reto Brun, Francois Nosten, Laurent Renia, Veronique Dartois, Thomas H. Keller, David A. Fidock, Elizabeth A. Winzeler, Thierry T. Diagana Spiroindolones, a potent compound class for the treatment of malaria. Science. Vol.329, No.5996 (2010), 1175-1180. doi:10.1126/science.1193225 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/29981
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Spiroindolones, a potent compound class for the treatment of malaria
Author(s)
Matthias Rottmann
Case McNamara
Bryan K.S. Yeung
Marcus C.S. Lee
Bin Zou
Bruce Russell
Patrick Seitz
David M. Plouffe
Neekesh V. Dharia
Jocelyn Tan
Steven B. Cohen
Kathryn R. Spencer
Gonzalo E. González-Páez
Suresh B. Lakshminarayana
Anne Goh
Rossarin Suwanarusk
Timothy Jegla
Esther K. Schmitt
Hans Peter Beck
Reto Brun
Francois Nosten
Laurent Renia
Veronique Dartois
Thomas H. Keller
David A. Fidock
Elizabeth A. Winzeler
Thierry T. Diagana
Case McNamara
Bryan K.S. Yeung
Marcus C.S. Lee
Bin Zou
Bruce Russell
Patrick Seitz
David M. Plouffe
Neekesh V. Dharia
Jocelyn Tan
Steven B. Cohen
Kathryn R. Spencer
Gonzalo E. González-Páez
Suresh B. Lakshminarayana
Anne Goh
Rossarin Suwanarusk
Timothy Jegla
Esther K. Schmitt
Hans Peter Beck
Reto Brun
Francois Nosten
Laurent Renia
Veronique Dartois
Thomas H. Keller
David A. Fidock
Elizabeth A. Winzeler
Thierry T. Diagana
Other Contributor(s)
Swiss Tropical and Public Health Institute (Swiss TPH)
Universitat Basel
The Genomics Institute of the Novartis Research Foundation
Novartis Institute for Tropical Diseases Pte. Ltd.
Columbia University Medical Center
Agency for Science, Technology and Research, Singapore
National University of Singapore
Scripps Research Institute
Pennsylvania State University
Novartis International AG
Shoklo Malaria Research Unit
Mahidol University
Nuffield Department of Clinical Medicine
Universitat Basel
The Genomics Institute of the Novartis Research Foundation
Novartis Institute for Tropical Diseases Pte. Ltd.
Columbia University Medical Center
Agency for Science, Technology and Research, Singapore
National University of Singapore
Scripps Research Institute
Pennsylvania State University
Novartis International AG
Shoklo Malaria Research Unit
Mahidol University
Nuffield Department of Clinical Medicine
Abstract
Recent reports of increased tolerance to artemisinin derivatives - the most recently adopted class of antimalarials - have prompted a need for new treatments. The spirotetrahydro-β-carbolines, or spiroindolones, are potent drugs that kill the blood stages of Plasmodium falciparum and Plasmodium vivax clinical isolates at low nanomolar concentration. Spiroindolones rapidly inhibit protein synthesis in P. falciparum, an effect that is ablated in parasites bearing nonsynonymous mutations in the gene encoding the P-type cation-transporter ATPase4 (PfATP4). The optimized spiroindolone NITD609 shows pharmacokinetic properties compatible with once-daily oral dosing and has single-dose efficacy in a rodent malaria model.